ESBL PREVALANCE IN URINE SPECIMENSOF CANCER PATIENTS AT A TERTIARY CARE CANCER CENTRE IN KERALA

Authors

  • SAJANI SAMUEL Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.
  • Vismaya Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.
  • Parthiban Rudrapathy Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.
  • Saravanan Murugesan Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.
  • Sarath KE Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i6.45282

Keywords:

Extended-spectrum β-lactamase, Gram-negative bacilli, Urinary tract infection

Abstract

Objective: The objective of this study documents the prevalence of extended-spectrum beta-lactamase (ESBL)-producing multiple drug resistance uropathogens reported prospectively for a period of 3 months from February 2020 to April 2020 and its susceptibility to the commonly recommended antibiotics for urinary tract infections (UTI).

Methods: Identification and characterization of the uro-pathogens from 200 samples were done by routine smear microscopy, culturing, Kirby–Bauer disc-diffusion assay, and double disc synergy test.

Results: Thirty percent of samples were culture-positive pointing Escherichia coli, Klebsiella pneumoniae, Pseudomonas Aeruginosa, and Serratia marcescens (51.9%, 36.5%, 9.61%, and 1.92%, respectively). Almost all ESBL producers were found to be multi-drug resistant that includes E. coli (56.6%), K. pneumoniae (36.74%) and P. aeruginosa (6.66%) warranting prompt need of surveillance for effective clinical management.

Conclusion: The current study pointed the emergence and incidence of ESBL producing Gram-negative bacilli that are multi-drug resistant and causing UTI among cancer patients.

Downloads

Download data is not yet available.

References

Arturo A, Ana E, Juan A, Manuel MJ, Nogueira JM. Prospective cohort study of risk factors for extended-spectrumβ-lactamase-producing E. coli Urinary tract infections in elderly patients admitted to hospital. Int J Clin Pract 2017;71:9.

Fatima J, Oiuwafemi T, Daniel M, Yahya Y, Tanko Z, Shuaibu Y. Extended-Spectrum beta-lactamase production and antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria. Annals of Tropical Pathology: 2018;12.

Helen SL, Le J, editors. Urinary Tract Infection, PSAP Book Publication, Infectious diseases. Vol. 1. 2018.

Jhang JF, Kuo HC. Recent advances in recurrent urinary tract infections from pathogenesis and biomarkers to prevention. Ci Ji Yi Xue Za Zhi 2017;29:131-7.

Mukta K, Nazneen S, Prasanna B. Urinary tract infection in cancer patients at a government cancer hospital Aurangabad, India. Int J Curr Microbiol Appl Sci 2017;5:2259-63.

Ganesh R, Shrestha D, Bhattachan B, Rai G. Epidemiology of urinary tract infection and antimicrobial resistance in a pediatric hospital in Nepal. BMC Infect Dis 2019;19:420.

Al Yousef SA, Younis S, Farrag E, Moussa HS, Bayoumi FS, Ali AM. Clinical and laboratory profile of urinary tract infections associated with extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. Ann Clin Lab Sci 2016;46:393-400.

Sahni RD, Mathai D, Sudarsanam TD, Balaji V, Brahamadathan KN, Jesudasan MV, et al. Extended-spectrum beta-lactamase producers: Detection for the diagnostic laboratory. J Glob Infect Dis 2018;10:140-6.

Sayed SA, Ali S, Abdulaziz AA, Ibrahim HB, Badr NA. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. Int J Health Sci (Qassim) 2019;13:48-55.

Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of Clinical Microbiology. 10th ed. Washington, DC: American Society of Microbiology; 2011. p. 145.a

Published

07-06-2023

How to Cite

SAMUEL, S., Vismaya, P. Rudrapathy, S. Murugesan, and S. KE. “ESBL PREVALANCE IN URINE SPECIMENSOF CANCER PATIENTS AT A TERTIARY CARE CANCER CENTRE IN KERALA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 16, no. 6, June 2023, pp. 67-70, doi:10.22159/ajpcr.2023.v16i6.45282.

Issue

Section

Original Article(s)